IMMIMMUTEP LIMITED

Announcement history available from 1 August 2025

Fromto
Date / TimeTitleTypeMSReport Codes
20 Aug 2026, 17:58Immutep Corporate PresentationPresentations03026
30 July 2026, 18:24Immutep Quarterly Activities Report and Appendix 4CQuarterly ReportsMS19004, 19009
24 July 2026, 19:01Abstract Accepted for Presentation at ESMO Congress 2026Company Administration12008
14 July 2026, 22:11Fourth U.S. Patent Secured for Efti and PD-1 CombinationCompany Update11001
13 July 2026, 19:38TACTI-004 Update & Positive Mature Data from INSIGHT-003Company UpdateMS11001
1 July 2026, 18:14Ceasing to be a substantial holderSubstantial Holders02003
17 June 2026, 18:22Becoming a substantial holderSubstantial Holders02001
16 June 2026, 18:16Ceasing to be a substantial holderSubstantial Holders02003
15 June 2026, 18:19Becoming a substantial holderSubstantial Holders02001
10 June 2026, 18:19Ceasing to be a substantial holderSubstantial Holders02003
10 June 2026, 03:58Ceasing to be a substantial holderSubstantial Holders02003
9 June 2026, 18:13Change in substantial holdingSubstantial Holders02002
9 June 2026, 18:12Becoming a substantial holderSubstantial Holders02001
5 June 2026, 03:30Change in substantial holdingSubstantial Holders02002
4 June 2026, 18:23Immutep Presents Positive IMP761 Phase I Data at EULAR 2026Company Update11001
30 May 2026, 03:03Change in substantial holdingSubstantial Holders02002
28 May 2026, 19:18Efti immune activation associated with improved survivalCompany Update11001
28 May 2026, 04:51Change in substantial holdingSubstantial Holders02002
11 May 2026, 18:16Ceasing to be a substantial holderSubstantial Holders02003
30 Apr 2026, 19:21Immutep Receives Nasdaq Notice of Bid Price DeficiencyCompany Administration12008
30 Apr 2026, 19:01Immutep Quarterly Activities Report and Appendix 4CQuarterly ReportsMS19003, 19008
27 Apr 2026, 18:15Change in substantial holdingSubstantial Holders02002
27 Apr 2026, 18:13Change in substantial holdingSubstantial Holders02002
23 Apr 2026, 18:15Change in substantial holdingSubstantial Holders02002
22 Apr 2026, 20:05Abstract on Efti accepted for presentation at ASCO 2026Company Administration12008
17 Apr 2026, 18:22Change in substantial holdingSubstantial Holders02002
15 Apr 2026, 19:27Immutep receives FDA ODD for Efti in Soft Tissue SarcomaCompany UpdateMS11001
13 Apr 2026, 18:17Change in substantial holdingSubstantial Holders02002
10 Apr 2026, 18:19Change in substantial holdingSubstantial Holders02002
8 Apr 2026, 20:06Immutep Investor UpdateCompany Update11001
20 Mar 2026, 19:18Change in substantial holdingSubstantial Holders02002
20 Mar 2026, 19:18Change in substantial holdingSubstantial Holders02002
20 Mar 2026, 00:24Ceasing to be a substantial holder from IFLSubstantial Holders02003
19 Mar 2026, 19:20Update on Phase I Study of IMP761 for Autoimmune DiseasesCompany UpdateMS11001
19 Mar 2026, 19:19Change in substantial holdingSubstantial Holders02002
19 Mar 2026, 19:16Change in substantial holdingSubstantial Holders02002
19 Mar 2026, 05:16Ceasing to be a substantial holderSubstantial Holders02003
18 Mar 2026, 04:16Becoming a substantial holderSubstantial Holders02001
17 Mar 2026, 19:20Change in substantial holdingSubstantial Holders02002
13 Mar 2026, 19:57Reinstatement to QuotationReinstatementMS09002
13 Mar 2026, 19:57TACTI-004 to be discontinued following futility analysisCompany UpdateMS11001
11 Mar 2026, 20:58Suspension from QuotationTrading Halt / SuspensionMS09001
7 Mar 2026, 04:35Trading HaltTrading Halt / SuspensionMS09007
25 Feb 2026, 20:07Half Yearly Report and AccountsFinancial ResultsMS03004, 03009, 03010, 03015, 03019
11 Feb 2026, 19:20Change in substantial holdingSubstantial Holders02002
6 Feb 2026, 19:19Immutep Achieves 50% Enrolment in Global TACTI-004-1L NSCLCCompany UpdateMS11001
5 Feb 2026, 19:15Change in substantial holdingSubstantial Holders02002
29 Jan 2026, 22:36Immutep Quarterly Activities Report and Appendix 4CQuarterly ReportsMS19002, 19007
31 Dec 2025, 19:27Change in substantial holdingSubstantial Holders02002
22 Dec 2025, 19:25Positive Update on IMP761 Phase 1Company UpdateMS11001
1–50 of 82
1 / 2